

R&D Media Day 2019

Welcome to the Novartis R&D Media Day, taking place on September 02-03, 2019 in Basel. During this exclusive event, you will have the opportunity to hear from our experts on the latest in the world of Research and Development at Novartis. Key topics include how we are approaching Cell & Gene therapies and what is to come, how we are using Data & Digital technologies to advance drug discovery, and the R&D Pipeline including the decision-making process behind this.

On this page, you will find all the information you need, including the agenda, the speaker biographies, presentations, and respective imagery.

We look forward to seeing you there!

Learn more about R&D at Novartis and connect with us online

Tab:

Agenda

September 02, 2019

Basel Campus, Visitor Center (Fabrikstrasse 6)

14:15	Arrival at campus and registration	Novartis campus site map (PDF 0.1 MB) ^[1]
14:45	Welcome to the Novartis Campus in Basel	Markus Jaggi , Head External Communications Europe / Asia
15:00 – 18:00	Visit to the Novartis Sense Bridge NIBR lab tours	
15:00 – 18:00	Selected interview slots	
Dinner	<i>Please check with your Novartis Country contact</i>	

September 03, 2019

Basel Campus, Fabrikstrasse 16, P22 Auditorium

8:30	Arrival at campus and registration	Novartis campus site map (PDF 0.1 MB) ^[1]
------	------------------------------------	--

9:00	Welcome, Re-imagine Medicine - Novartis mission	John Tsai , Global Head Novartis Global Drug Development (GDD)
9:10	<p>Research @ Novartis</p> <ul style="list-style-type: none"> • Overview of Novartis Institutes for Biomedical Research (NIBR) and our research strategy • Highlights key projects in the pipeline • Collaboration with external partners • The development of a drug – from NIBR to GDD and how we collaborate 	Ronenn Roubenoff , Global Head Translational Medicine Discovery & Profiling and Global Head, Musculoskeletal Disease Translational Medicine
9:40	<p>R&D pipeline overview</p> <ul style="list-style-type: none"> • How Novartis manages its portfolio • What's next? Deep dive into future areas 	Amit Agrawal , Head Portfolio Strategy & Management, GDD
10:10	Q&A – research and pipeline	Ronenn Roubenoff Amit Agrawal
		Sreejit Mohan , Global Head External Communications (moderation)
10:40 - 11:10	Coffee break / Selected interview slots	
11:10	Data & digital from an R&D perspective: Panel discussion	
	Our strategy, partnerships, and commitment to digital therapeutics	Thorsten Rall , Head of Digital Strategy & Program Ops, Chief Digital Office (CDO)
	The use of AI/data science in decision-making	Luca Finelli , Head DSAI Insights Strategy & Design, CDO
	Clinical trial experiences	Sam Hariry , Head Clinical Strategy and Operations, Translational Medicine, NIBR

	Miriam Donaldson , Head HR Global Digital Function (moderation)	
11:50 - 13:15	Lunch break Selected interview slots	
13:15	Cell & Gene (C&G) therapies: Presentations	
	Setting the scene:	Stephen Moran , Global Head Strategy
	<ul style="list-style-type: none"> • Why Novartis believes in C&G • Overview C&G and landscape • AAV, CART, CRISPR 	
	Overview by disease area:	
	Oncology: CART, Pediatric and young adult acute lymphoblastic leukemia (pALL), Adult diffuse large B-cell lymphoma (DLBCL)	Emanuele Ostuni , Head of Cell & Gene Therapy
	Ophthalmology: Inherited Retinal Disease (IRD)	Nikolaos Tripodis , Global Business Franchise Head Ophthalmology
	Neuroscience: Spinal Muscular Atrophy (SMA)	Petra Kaufmann , VP, R&D Translational Medicine, Avexis
	Market access & patient access	Gesa Pellier , Head Global Patient Access
14:15 - 14:45	Coffee break / Selected interview slots	
14:45	C&G – moderated panel discussion	Stephen Moran Gesa Pellier Emanuele Ostuni Nikolaos Tripodis Petra Kaufmann
		Sreejit Mohan (moderation)
15:45	Close presentation session	Stephen Moran
16:00 - 17:30	Selected interview slots	

Speaker overview ^[2]

Amit Agrawal



Head, Portfolio Strategy & Management, Global Drug Development

Amit leads the Portfolio Strategy and Management team, and is a member of the Development Committee of Novartis (DCN) and Innovative Medicines Board (IMB). With an overall aim to optimize Novartis' late-stage pipeline, Amit's areas of responsibility include in- and out-bound BD&L diligence, late-stage program management, portfolio governance and analytics, and operations for the DCN and IMB governance boards. Amit joined Novartis in Oct 2018 from Amgen where he was Head of Corporate Strategy.

Key topics:

- Novartis R&D strategy and approach
- Drug development
- Late-stage pipeline
- Portfolio management

Languages spoken: English, Hindi

[Read Biography \(PDF 0.1 MB\)](#) ^[3]

Miriam Donaldson, MBA



Global Head of People and Organization Digital

Miriam Donaldson, MBA is the Head of People and Organization for Digital at Novartis. In this role, she is partnering with the Chief Digital Officer and team to lead the digital transformation of Novartis in the company's pursuit to become the best innovative medicines company powered by data and digital. Since joining Novartis in 2004, Miriam has held positions of increasing scope and complexity across the value chain at Novartis including Drug Development, Marketing, and Operations.

Key topics:

- Digital transformation
- Talent
- Innovation
- Culture
- Organization design
- Capability building

Languages spoken: English, German

[Read Biography \(PDF 0.1 MB\)](#) ^[4]

Luca Finelli

Vice President and Head, Insights Strategy and Design Data Science & AI / Chief Digital Office



Luca is the Head of Insights Strategy & Design for the newly formed Data Science and AI unit in Novartis Digital. He is also Program Owner of Nerve Live, a next generation advanced analytics platform exploiting machine learning and cutting-edge data science, which delivered SENSE, Novartis' first Insights Center for Clinical Trials. His passion for computational intelligence goes back to the early nineties when he got a first glimpse of the future of AI while developing neural networks.

Key topics:

- How we are transforming Novartis to become a leading pharma company powered by data science and AI

- Embedding data science into the fabric of Novartis - Enabling the emergence of “Citizen Data Scientists”
- Culture change – Letting the data speak
- Need for associates to learn how to use the data and insights in their area
- Creating physical insights centers like SENSE
- What we learned from other industries
- How AI is changing the way knowledge gets created

Languages spoken: English, Italian, German, French

[Read Biography \(PDF 0.1 MB\)](#) ^[5]

Sam Hariry



Head of Clinical Strategy and Operations, NIBR

Sam Hariry is leading the Clinical Strategy and Operations team within the Translational Medicines group at NIBR. He is a strategic leader with over 15 years of experience in the pharmaceutical industry, specifically early phase drug development, clinical operations and profiling development to support drug registrations. He is experienced in working in new indications, established and rare diseases and orphan indications and portfolio management and resource planning for projects throughout multiple phases of development, pre-clinical to late stage.

Key topics:

- Novartis collaborations with partners on digitally enabled clinical trials and patient outreach
- Novartis data & digital strategy (NIBR focus)
- Novartis digital endpoints
- Patient insights we get from data and digital
- Novartis digital therapeutics

Languages spoken: English

[Read Biography \(PDF 0.1 MB\)](#) ^[6]

Petra Kaufmann



Vice President R&D Translational Medicine, AveXis

An experienced physician-scientist, Petra's interest in developing better therapies for neurological diseases led her to join AveXis in 2018, where she focuses on translational medicine and gene therapy for rare diseases.

Petra previously held roles in academia and government and is skilled in clinical trial design and implementation, with a proven track record in managing large, collaborative, multi-disciplinary research programs.

Key topics:

- Research
- Gene therapy
- Clinical trial design

Languages spoken: English, German, French

[Read Biography \(PDF 0.1 MB\)](#) ^[7]

Stephen Moran, Ph.D.



Global Head of Strategy for Novartis

Stephen Moran, Ph.D., has been Global Head of Strategy for Novartis since 2016. Mr. Moran

joined Novartis in 2015 as Strategic Assistant to the CEO. Prior to that, he was an associate principal at McKinsey & Company, serving as a leader in the healthcare practice. His work there focused on health system sustainability, research and development strategy, and the economic analysis of clinical interventions across disease pathways.

Key topics:

- Overall Novartis strategy
- Novartis R&D strategy
- Novartis portfolio strategy
- Cell & Gene therapies
- Economic value of therapies

Languages spoken: English

[Read Biography](#) ^[8]

Emanuele Ostuni, PhD



Head of Europe Cell and Gene Therapies Novartis Oncology

Emanuele Ostuni is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees the commercialization of this portfolio in Europe.

Key topics:

- CART
- Science
- Medicine
- Data
- Market access
- Value based pricing
- Innovative pricing schemes
- Ethics

- Access
- Manufacturing
- Operations
- Future of cancer care
- Culture
- Collaboration

Languages spoken: Italian, English, German

[Read Biography \(PDF 0.1 MB\)](#) ^[9]

Gesa Pellier



Head Global Patient Access, Novartis Pharma AG

Gesa heads the Novartis Global Patient Access (GPA) team since 2013. In this role, she is responsible for ensuring appropriate patient-centric, outcome-focused value demonstration and access plans and their execution for all Novartis Pharma therapy areas and products/programs, throughout development and post-approval, worldwide.

Key topics:

- Market access
- Pricing & reimbursement
- Health economics and outcome research

Languages spoken: German, English

[Read Biography \(PDF 0.1 MB\)](#) ^[10]

Thorsten Rall



Global Head of Digital Strategy and Program Operations Novartis Digital/Group

Thorsten Rall is the Global Head of Digital Strategy and Program Operations at Novartis. In this role, he and his team are responsible for defining strategic digital priority areas for Novartis globally and working with the organization in implementing those at scale to meaningfully impact Novartis's business objectives in innovation, commercial, and operations. In addition, he is driving a select number of global partnerships in the digital space aiming at positioning Novartis at the forefront in future healthcare settings. He is further setting the agenda for continuously refining the operating model of Novartis in the digital space.

Key topics:

- Strategic priority areas to address with data and technology in research and development
- Digital in clinical trial operations
- Digital Therapeutics
- Data42
- Key enablers, including capability building programs, data strategy.

Languages spoken: Italian, English, German

[Read Biography \(PDF 0.1 MB\)](#) ^[11]

Ronenn Roubenoff, MD, MHS



Global Head, Translational Medicine Discovery & Profiling and Global Head, Musculoskeletal

Disease Translational Medicine

Ronenn Roubenoff, MD, MHS, is the Global Head, Translational Medicine Discovery & Profiling and Global Head of Musculoskeletal Translational Medicine. Prior to joining Novartis in 2009 as Global Translational Medicine Head, Musculoskeletal Diseases, followed by multiple assignments within Translational Medicine in both Cambridge and Basel, Ronenn led the Translational Medicine and Early Development efforts for the Immunology Group at Biogen Idec, Inc. from 2007 through 2009. Earlier in his career, he spent four years as Senior Director of Molecular Medicine at Millennium Pharmaceuticals, and was the Director of the Nutrition, Exercise Physiology, and Sarcopenia Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging.

Key topics:

- Research strategy and pipeline
- Digital Endpoints
- Research partnerships and collaboration

Languages spoken: English, Hebrew, French, German

[Read Biography \(PDF 0.1 MB\)](#) ^[12]

Nikolaos Tripodis



Global Business Franchise Head Ophthalmology

Nikolaos (Nikos) Tripodis, a medical geneticist by training, leads a global organization that brings Ophthalmology products to physicians and patients, spanning eye diseases in both the front and back of the eye.

Key topics:

- Inherited retinal disease
- RPE65
- Ophthalmology business
- Pipeline and people

Languages spoken: English, Greek

[Read Biography \(PDF 0.1 MB\)](#) ^[13]

Resources ^[14]

Source URL: <https://www.novartis.com/news/media-events/rd-media-day-2019>

Links

- [1] <https://www.novartis.com/sites/www.novartis.com/files/novartis-campus.pdf>
- [2] <https://www.novartis.com/news/media-events/rd-media-day-2019#tab-2>
- [3] <https://www.novartis.com/sites/www.novartis.com/files/amit-agrawal-biography.pdf>
- [4] <https://www.novartis.com/sites/www.novartis.com/files/miriam-donaldson-biography.pdf>
- [5] <https://www.novartis.com/sites/www.novartis.com/files/luca-finelli-biography.pdf>
- [6] <https://www.novartis.com/sites/www.novartis.com/files/sam-hariry-biography.pdf>
- [7] <https://www.novartis.com/sites/www.novartis.com/files/petra-kaufmann-biography.pdf>
- [8] <https://www.novartis.com/our-company/executive-committee/stephen-moran>
- [9] <https://www.novartis.com/sites/www.novartis.com/files/emanuele-ostuni-biography.pdf>
- [10] <https://www.novartis.com/sites/www.novartis.com/files/gesa-pellier-biography.pdf>
- [11] <https://www.novartis.com/sites/www.novartis.com/files/thorsten-rall-biography.pdf>
- [12] https://www.novartis.com/sites/www.novartis.com/files/ronenn-roubenoff-biography_0.pdf
- [13] <https://www.novartis.com/sites/www.novartis.com/files/nikolaos-tripodis-biography.pdf>
- [14] <https://www.novartis.com/news/media-events/rd-media-day-2019#tab-3>